Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $51.69 million. The enterprise value is $47.87 million.
| Market Cap | 51.69M |
| Enterprise Value | 47.87M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.86 million shares outstanding. The number of shares has increased by 4.21% in one year.
| Current Share Class | 10.86M |
| Shares Outstanding | 10.86M |
| Shares Change (YoY) | +4.21% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 13.39% |
| Owned by Institutions (%) | 48.95% |
| Float | 9.41M |
Valuation Ratios
The trailing PE ratio is 29.74 and the forward PE ratio is 25.05.
| PE Ratio | 29.74 |
| Forward PE | 25.05 |
| PS Ratio | 2.49 |
| Forward PS | 2.18 |
| PB Ratio | 4.32 |
| P/TBV Ratio | 4.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 27.57 |
| EV / Sales | 2.31 |
| EV / EBITDA | 27.15 |
| EV / EBIT | 29.15 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.07 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | n/a |
| Interest Coverage | 1,642.00 |
Financial Efficiency
Return on equity (ROE) is 16.10% and return on invested capital (ROIC) is 20.60%.
| Return on Equity (ROE) | 16.10% |
| Return on Assets (ROA) | 7.33% |
| Return on Invested Capital (ROIC) | 20.60% |
| Return on Capital Employed (ROCE) | 13.21% |
| Weighted Average Cost of Capital (WACC) | 12.43% |
| Revenue Per Employee | $575,611 |
| Profits Per Employee | $48,222 |
| Employee Count | 36 |
| Asset Turnover | 1.48 |
| Inventory Turnover | 2.37 |
Taxes
In the past 12 months, Nephros has paid $16,000 in taxes.
| Income Tax | 16,000 |
| Effective Tax Rate | 0.91% |
Stock Price Statistics
The stock price has increased by +10.70% in the last 52 weeks. The beta is 1.53, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +10.70% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 3.95 |
| Relative Strength Index (RSI) | 67.77 |
| Average Volume (20 Days) | 22,942 |
Short Selling Information
The latest short interest is 37,493, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 37,493 |
| Short Previous Month | 31,336 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.40% |
| Short Ratio (days to cover) | 4.15 |
Income Statement
In the last 12 months, Nephros had revenue of $20.72 million and earned $1.74 million in profits. Earnings per share was $0.16.
| Revenue | 20.72M |
| Gross Profit | 12.70M |
| Operating Income | 1.64M |
| Pretax Income | 1.75M |
| Net Income | 1.74M |
| EBITDA | 1.76M |
| EBIT | 1.64M |
| Earnings Per Share (EPS) | $0.16 |
Balance Sheet
The company has $4.70 million in cash and $872,000 in debt, with a net cash position of $3.83 million or $0.35 per share.
| Cash & Cash Equivalents | 4.70M |
| Total Debt | 872,000 |
| Net Cash | 3.83M |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | 11.97M |
| Book Value Per Share | 1.10 |
| Working Capital | 10.25M |
Cash Flow
| Operating Cash Flow | -661,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 121,000 |
| Net Borrowing | -6,000 |
| Free Cash Flow | -661,000 |
| FCF Per Share | -$0.06 |
Margins
Gross margin is 61.26%, with operating and profit margins of 7.92% and 8.38%.
| Gross Margin | 61.26% |
| Operating Margin | 7.92% |
| Pretax Margin | 8.45% |
| Profit Margin | 8.38% |
| EBITDA Margin | 8.51% |
| EBIT Margin | 7.92% |
| FCF Margin | n/a |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.21% |
| Shareholder Yield | -4.21% |
| Earnings Yield | 3.36% |
| FCF Yield | -1.28% |
Analyst Forecast
The average price target for Nephros is $6.25, which is 31.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.25 |
| Price Target Difference | 31.30% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.68% |
| EPS Growth Forecast (3Y) | 42.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -3.3 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.3 |
| Piotroski F-Score | 3 |